Verily Life Sciences, an Alphabet subsidiary that’s using artificial intelligence and data science to make a splash in precision medicine, hired drug distributor McKesson’s chief compliance officer as general counsel.

Laura O’Donnell is coming aboard at a time of rapid-fire change for the 8-year-old, San Francisco-based company. Since last fall, Verily has made sweeping leadership changes, including the appointment of a new CEO, narrowed its focus, laid off 15% of its 1,600 employees and received a $1 billion infusion from Alphabet to fund its next phase of growth.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]